Total Skin Electron Beam and Non-Myeloablative Allogeneic Hematopoietic Stem-Cell Transplantation in Advanced Mycosis Fungoides and Sézary Syndrome
- 10 May 2010
- journal article
- clinical trial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 28 (14), 2365-2372
- https://doi.org/10.1200/jco.2009.25.8301
Abstract
Purpose: Transformed mycosis fungoides (MF) and Sézary syndrome (SS) are currently incurable. We studied the safety and efficacy of total skin electron beam with allogeneic hematopoietic stem-cell transplantation (HSCT) in patients with cutaneous T-cell lymphoma (CTCL). Patients and Methods: Nineteen patients with advanced CTCL (median age, 50 years; four prior therapies) underwent total skin electron beam radiation followed by allogeneic HSCT between July 2001 and July 2008. Sixteen patients were conditioned with fludarabine (125 mg/m2) and melphalan (140 mg/m2) plus thymoglobulin (for mismatched donors). Graft-versus-host disease (GVHD) prophylaxis was with tacrolimus/mini methotrexate. Results: Eighteen patients experienced engraftment, and one died as a result of sepsis on day 16. Median time to recovery of absolute neutrophil count (ANC) was 12 days. Fifteen achieved full donor chimerism, 12 had acute GVHD, and 12 were treated for chronic GVHD. The overall intent-to-treat response was 68%, and the complete response rate was 58%. Four of six patients died in complete remission as a result of bacterial sepsis (n = 2), chronic GVHD and fungal infection (n = 1), or lung cancer (n = 1); only two died as a result of progressive disease. Eight experienced relapse in skin; five regained complete response with reduced immunosuppression or donor lymphocyte infusions. Eleven of 13 are currently in complete remissions, with median follow-up of 19 months (range, 1.3 to 8.3 years). Median overall survival has not been reached. Conclusion: Total skin electron beam followed by allogeneic stem-cell transplantation merits additional evaluation for a selected group of patients with refractory, advanced, cutaneous T-cell lymphoma with evidence for graft-versus-tumor effect.Keywords
This publication has 28 references indexed in Scilit:
- Durable Clinical, Cytogenetic, and Molecular Remissions After Allogeneic Hematopoietic Cell Transplantation for Refractory Sezary Syndrome and Mycosis FungoidesJournal of Clinical Oncology, 2005
- WHO-EORTC classification for cutaneous lymphomasBlood, 2005
- High-dose therapy and autologous stem cell transplantation in relapsing cutaneous lymphomaBone Marrow Transplantation, 2004
- The Sézary syndrome: hematologic criteriaHematology/Oncology Clinics of North America, 2003
- High-dose therapy and bone marrow transplantation in cutaneous T-cell lymphomaHematology/Oncology Clinics of North America, 2003
- Long-term remission after allogeneic hematopoietic stem cell transplantation for refractory cutaneous T-cell lymphoma.Archives of Dermatology, 2002
- Diagnostic and prognostic importance of T‐cell receptor gene analysis in patients with Sézary syndromeCancer, 2001
- Autologous Peripheral Blood Stem Cell Transplantation in Tumor‐stage Mycosis Fungoides: Predictors of Disease‐free SurvivalAnnals of the New York Academy of Sciences, 2001
- Prognosis in cutaneous T-cell lymphoma by skin stage: Long-term survival in 489 patientsJournal of the American Academy of Dermatology, 1999
- Clinical Characteristics and Long-term Outcome of Patients With Generalized Patch and/or Plaque (T2) Mycosis FungoidesArchives of Dermatology, 1999